<VariationArchive VariationID="851041" VariationName="NM_017849.4(TMEM127):c.383dup (p.Tyr129fs)" VariationType="Duplication" Accession="VCV000851041" Version="7" RecordType="classified" NumberOfSubmissions="1" NumberOfSubmitters="1" DateLastUpdated="2024-06-23" DateCreated="2020-04-15" MostRecentSubmission="2024-02-20">
  <RecordStatus>current</RecordStatus>
  <Species>Homo sapiens</Species>
  <ClassifiedRecord>
    <SimpleAllele AlleleID="827135" VariationID="851041">
      <GeneList>
        <Gene Symbol="TMEM127" FullName="transmembrane protein 127" GeneID="55654" HGNC_ID="HGNC:26038" Source="submitted" RelationshipType="within single gene">
          <Location>
            <CytogeneticLocation>2q11.2</CytogeneticLocation>
            <SequenceLocation Assembly="GRCh38" AssemblyAccessionVersion="GCF_000001405.38" AssemblyStatus="current" Chr="2" Accession="NC_000002.12" start="96248514" stop="96265997" display_start="96248514" display_stop="96265997" Strand="-" />
            <SequenceLocation Assembly="GRCh37" AssemblyAccessionVersion="GCF_000001405.25" AssemblyStatus="previous" Chr="2" Accession="NC_000002.11" start="96915945" stop="96931750" display_start="96915945" display_stop="96931750" Strand="-" />
          </Location>
          <OMIM>613403</OMIM>
          <Haploinsufficiency last_evaluated="2021-07-13" ClinGen="https://www.ncbi.nlm.nih.gov/projects/dbvar/ISCA/isca_gene.cgi?sym=TMEM127">Sufficient evidence for dosage pathogenicity</Haploinsufficiency>
          <Triplosensitivity last_evaluated="2021-07-13" ClinGen="https://www.ncbi.nlm.nih.gov/projects/dbvar/ISCA/isca_gene.cgi?sym=TMEM127">No evidence available</Triplosensitivity>
          <Property>gene_acmg_incidental_2021</Property>
          <Property>gene_acmg_incidental_2022</Property>
        </Gene>
      </GeneList>
      <Name>NM_017849.4(TMEM127):c.383dup (p.Tyr129fs)</Name>
      <CanonicalSPDI>NC_000002.12:96254858:C:CC</CanonicalSPDI>
      <VariantType>Duplication</VariantType>
      <Location>
        <CytogeneticLocation>2q11.2</CytogeneticLocation>
        <SequenceLocation Assembly="GRCh38" AssemblyAccessionVersion="GCF_000001405.38" forDisplay="true" AssemblyStatus="current" Chr="2" Accession="NC_000002.12" start="96254858" stop="96254859" display_start="96254858" display_stop="96254859" variantLength="1" positionVCF="96254858" referenceAlleleVCF="G" alternateAlleleVCF="GC" />
        <SequenceLocation Assembly="GRCh37" AssemblyAccessionVersion="GCF_000001405.25" AssemblyStatus="previous" Chr="2" Accession="NC_000002.11" start="96920596" stop="96920597" display_start="96920596" display_stop="96920597" variantLength="1" positionVCF="96920596" referenceAlleleVCF="G" alternateAlleleVCF="GC" />
      </Location>
      <ProteinChange>Y129fs</ProteinChange>
      <HGVSlist>
        <HGVS Assembly="GRCh37" Type="genomic, top-level">
          <NucleotideExpression sequenceAccessionVersion="NC_000002.11" sequenceAccession="NC_000002" sequenceVersion="11" change="g.96920597dup" Assembly="GRCh37">
            <Expression>NC_000002.11:g.96920597dup</Expression>
          </NucleotideExpression>
        </HGVS>
        <HGVS Assembly="GRCh38" Type="genomic, top-level">
          <NucleotideExpression sequenceAccessionVersion="NC_000002.12" sequenceAccession="NC_000002" sequenceVersion="12" change="g.96254859dup" Assembly="GRCh38">
            <Expression>NC_000002.12:g.96254859dup</Expression>
          </NucleotideExpression>
        </HGVS>
        <HGVS Type="genomic">
          <NucleotideExpression sequenceAccessionVersion="NG_027695.1" sequenceAccession="NG_027695" sequenceVersion="1" change="g.16155dup">
            <Expression>NG_027695.1:g.16155dup</Expression>
          </NucleotideExpression>
        </HGVS>
        <HGVS Type="coding">
          <NucleotideExpression sequenceAccessionVersion="NM_001193304.3" sequenceAccession="NM_001193304" sequenceVersion="3" change="c.383dup">
            <Expression>NM_001193304.3:c.383dup</Expression>
          </NucleotideExpression>
          <ProteinExpression sequenceAccessionVersion="NP_001180233.1" sequenceAccession="NP_001180233" sequenceVersion="1" change="p.Tyr129fs">
            <Expression>NP_001180233.1:p.Tyr129fs</Expression>
          </ProteinExpression>
          <MolecularConsequence ID="SO:0001589" Type="frameshift variant" DB="SO" />
        </HGVS>
        <HGVS Type="coding">
          <NucleotideExpression sequenceAccessionVersion="NM_017849.4" sequenceAccession="NM_017849" sequenceVersion="4" change="c.383dup" MANESelect="true">
            <Expression>NM_017849.4:c.383dup</Expression>
          </NucleotideExpression>
          <ProteinExpression sequenceAccessionVersion="NP_060319.1" sequenceAccession="NP_060319" sequenceVersion="1" change="p.Tyr129fs">
            <Expression>NP_060319.1:p.Tyr129fs</Expression>
          </ProteinExpression>
          <MolecularConsequence ID="SO:0001589" Type="frameshift variant" DB="SO" />
        </HGVS>
        <HGVS Type="genomic">
          <NucleotideExpression sequenceAccessionVersion="LRG_528" sequenceAccession="LRG_528">
            <Expression>LRG_528:g.16155dup</Expression>
          </NucleotideExpression>
        </HGVS>
        <HGVS Type="coding">
          <NucleotideExpression sequenceAccessionVersion="LRG_528t1" sequenceAccession="LRG_528t1">
            <Expression>LRG_528t1:c.383dup</Expression>
          </NucleotideExpression>
        </HGVS>
      </HGVSlist>
      <XRefList>
        <XRef Type="rs" ID="1684169157" DB="dbSNP" />
      </XRefList>
    </SimpleAllele>
    <RCVList>
      <RCVAccession Title="NM_017849.4(TMEM127):c.383dup (p.Tyr129fs) AND Hereditary pheochromocytoma-paraganglioma" Accession="RCV001055349" Version="8">
        <ClassifiedConditionList TraitSetID="6283">
          <ClassifiedCondition DB="MedGen" ID="C1708353">Hereditary pheochromocytoma-paraganglioma</ClassifiedCondition>
        </ClassifiedConditionList>
        <RCVClassifications>
          <GermlineClassification>
            <ReviewStatus>criteria provided, single submitter</ReviewStatus>
            <Description DateLastEvaluated="2019-02-25" SubmissionCount="1">Pathogenic</Description>
          </GermlineClassification>
        </RCVClassifications>
      </RCVAccession>
    </RCVList>
    <Classifications>
      <GermlineClassification DateLastEvaluated="2019-02-25" NumberOfSubmissions="1" NumberOfSubmitters="1" DateCreated="2020-04-15" MostRecentSubmission="2024-02-20">
        <ReviewStatus>criteria provided, single submitter</ReviewStatus>
        <Description>Pathogenic</Description>
        <ConditionList>
          <TraitSet ID="6283" Type="Disease" ContributesToAggregateClassification="true">
            <Trait ID="9507" Type="Disease">
              <Name>
                <ElementValue Type="Alternate">Hereditary Paraganglioma-Pheochromocytoma Syndromes</ElementValue>
              </Name>
              <Name>
                <ElementValue Type="Alternate">Hereditary Paragangliomas and Pheochromocytomas</ElementValue>
              </Name>
              <Name>
                <ElementValue Type="Preferred">Hereditary pheochromocytoma-paraganglioma</ElementValue>
                <XRef ID="MONDO:0017366" DB="MONDO" />
              </Name>
              <Symbol>
                <ElementValue Type="Alternate">PGL-PCC</ElementValue>
              </Symbol>
              <AttributeSet>
                <Attribute Type="public definition">Hereditary paraganglioma-pheochromocytoma (PGL/PCC) syndromes are characterized by paragangliomas (tumors that arise from neuroendocrine tissues distributed along the paravertebral axis from the base of the skull to the pelvis) and pheochromocytomas (paragangliomas that are confined to the adrenal medulla). Sympathetic paragangliomas cause catecholamine excess; parasympathetic paragangliomas are most often nonsecretory. Extra-adrenal parasympathetic paragangliomas are located predominantly in the skull base and neck (referred to as head and neck PGL [HNPGL]) and sometimes in the upper mediastinum; approximately 95% of such tumors are nonsecretory. In contrast, sympathetic extra-adrenal paragangliomas are generally confined to the lower mediastinum, abdomen, and pelvis, and are typically secretory. Pheochromocytomas, which arise from the adrenal medulla, typically lead to catecholamine excess. Symptoms of PGL/PCC result from either mass effects or catecholamine hypersecretion (e.g., sustained or paroxysmal elevations in blood pressure, headache, episodic profuse sweating, forceful palpitations, pallor, and apprehension or anxiety). The risk for developing metastatic disease is greater for extra-adrenal sympathetic paragangliomas than for pheochromocytomas.</Attribute>
                <XRef ID="NBK1548" DB="GeneReviews" />
              </AttributeSet>
              <AttributeSet>
                <Attribute Type="GARD id" integerValue="11984" />
                <XRef ID="11984" DB="Office of Rare Diseases" />
              </AttributeSet>
              <Citation Type="review" Abbrev="GeneReviews">
                <ID Source="PubMed">20301715</ID>
                <ID Source="BookShelf">NBK1548</ID>
              </Citation>
              <Citation Type="general" Abbrev="ES, 2014">
                <ID Source="PubMed">24893135</ID>
              </Citation>
              <Citation Type="general" Abbrev="ASCO, 2014">
                <ID Source="PubMed">24493721</ID>
              </Citation>
              <Citation Type="general" Abbrev="NANETS, 2010">
                <ID Source="PubMed">20664475</ID>
                <ID Source="pmc">3419007</ID>
              </Citation>
              <Citation Type="general" Abbrev="KCRNC, 2013">
                <ID Source="PubMed">24319509</ID>
              </Citation>
              <Citation Type="Suggested Reading" Abbrev="NCI PDQ, Endocrine and Neuroendocrine Neoplasia genetics">
                <ID Source="PubMed">26389271</ID>
              </Citation>
              <Citation Type="Suggested Reading" Abbrev="NCI PDQ, Cancer Genetics Counseling">
                <ID Source="PubMed">26389258</ID>
              </Citation>
              <Citation Type="general" Abbrev="NANETS, 2021">
                <ID Source="PubMed">33939658</ID>
              </Citation>
              <XRef ID="29072" DB="Orphanet" />
              <XRef ID="C1708353" DB="MedGen" />
              <XRef ID="MONDO:0017366" DB="MONDO" />
            </Trait>
          </TraitSet>
        </ConditionList>
      </GermlineClassification>
    </Classifications>
    <ClinicalAssertionList>
      <ClinicalAssertion ID="2385170" SubmissionDate="2024-02-08" DateLastUpdated="2024-02-20" DateCreated="2020-04-15">
        <ClinVarSubmissionID localKey="6099138|MedGen:C1708353" submittedAssembly="GRCh37" />
        <ClinVarAccession Accession="SCV001219737" DateUpdated="2024-02-20" DateCreated="2020-04-15" Type="SCV" Version="5" SubmitterName="Invitae" OrgID="500031" OrganizationCategory="laboratory" OrgAbbreviation="Invitae" />
        <RecordStatus>current</RecordStatus>
        <Classification DateLastEvaluated="2019-02-25">
          <ReviewStatus>criteria provided, single submitter</ReviewStatus>
          <GermlineClassification>Pathogenic</GermlineClassification>
          <Comment>For these reasons, this variant has been classified as Pathogenic. This variant disrupts the C-terminus of the TMEM127 protein. Other variant(s) that disrupt this region (p.Gln157*,¬†p.Gln159*) have been determined to be pathogenic (PMID:¬†22419703, 20154675, Invitae). This suggests that variants that disrupt this region of the protein are likely to be causative of disease. This variant has not been reported in the literature in individuals with TMEM127-related conditions. This variant is not present in population databases (ExAC no frequency). This sequence change results in a premature translational stop signal in the TMEM127 gene (p.Tyr129Leufs*24). While this is not anticipated to result in nonsense mediated decay, it is expected to disrupt the last 110 amino acids of the TMEM127 protein.</Comment>
        </Classification>
        <Assertion>variation to disease</Assertion>
        <AttributeSet>
          <Attribute Type="AssertionMethod">Invitae Variant Classification Sherloc (09022015)</Attribute>
          <Citation>
            <ID Source="PubMed">28492532</ID>
          </Citation>
        </AttributeSet>
        <ObservedInList>
          <ObservedIn>
            <Sample>
              <Origin>germline</Origin>
              <Species TaxonomyId="9606">human</Species>
              <AffectedStatus>unknown</AffectedStatus>
            </Sample>
            <Method>
              <MethodType>clinical testing</MethodType>
            </Method>
            <ObservedData>
              <Attribute Type="Description">not provided</Attribute>
            </ObservedData>
          </ObservedIn>
        </ObservedInList>
        <SimpleAllele>
          <GeneList>
            <Gene Symbol="TMEM127" />
          </GeneList>
          <VariantType>Variation</VariantType>
          <AttributeSet>
            <Attribute Type="HGVS">NC_000002.11:g.96920596_96920597insC</Attribute>
          </AttributeSet>
        </SimpleAllele>
        <TraitSet Type="Disease">
          <Trait Type="Disease">
            <XRef DB="MedGen" ID="C1708353" Type="CUI" />
          </Trait>
        </TraitSet>
        <SubmissionNameList>
          <SubmissionName>SUB11431369</SubmissionName>
          <SubmissionName>SUB12508014</SubmissionName>
          <SubmissionName>SUB14200314</SubmissionName>
          <SubmissionName>SUB8755776</SubmissionName>
        </SubmissionNameList>
      </ClinicalAssertion>
    </ClinicalAssertionList>
    <TraitMappingList>
      <TraitMapping ClinicalAssertionID="2385170" TraitType="Disease" MappingType="XRef" MappingValue="C1708353" MappingRef="MedGen">
        <MedGen CUI="C1708353" Name="Hereditary pheochromocytoma-paraganglioma" />
      </TraitMapping>
    </TraitMappingList>
  </ClassifiedRecord>
</VariationArchive>

